The polymer used in the development of the new formulation demonstrated significant results compared to Systane, Alcon’s OTC dry eye product, in the clinical trials.
Particle Sciences CEO Mark Mitchnick said, "Particle Sciences has seen an increase in the number of client’s coming to us for ocular formulations. In this case, our staff came up with a new approach and worked with our client to take the idea from concept into clinical trials in a very short time."
Dry eye is a condition in which the eye fails to produce sufficient tears or the right quality of tears to keep it healthy and comfortable.